BR112016006664A2 - compostos para a inibição do crescimento celular desregulado - Google Patents

compostos para a inibição do crescimento celular desregulado

Info

Publication number
BR112016006664A2
BR112016006664A2 BR112016006664A BR112016006664A BR112016006664A2 BR 112016006664 A2 BR112016006664 A2 BR 112016006664A2 BR 112016006664 A BR112016006664 A BR 112016006664A BR 112016006664 A BR112016006664 A BR 112016006664A BR 112016006664 A2 BR112016006664 A2 BR 112016006664A2
Authority
BR
Brazil
Prior art keywords
compounds
cell growth
inhibition
unregulated cell
unregulated
Prior art date
Application number
BR112016006664A
Other languages
English (en)
Portuguese (pt)
Inventor
Pangavhane Kailas
Athavale Maithili
Original Assignee
Godavari Biorefineries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Godavari Biorefineries Ltd filed Critical Godavari Biorefineries Ltd
Publication of BR112016006664A2 publication Critical patent/BR112016006664A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BR112016006664A 2013-09-26 2014-09-26 compostos para a inibição do crescimento celular desregulado BR112016006664A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000622 WO2015044960A2 (en) 2013-09-26 2014-09-26 Compounds for inhibition of unregulated cell growth
IN3015MU2013 IN2013MU03015A (OSRAM) 2013-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
BR112016006664A2 true BR112016006664A2 (pt) 2017-08-01

Family

ID=52744636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006664A BR112016006664A2 (pt) 2013-09-26 2014-09-26 compostos para a inibição do crescimento celular desregulado

Country Status (8)

Country Link
US (1) US20160214941A1 (OSRAM)
EP (1) EP3049083A4 (OSRAM)
JP (1) JP2017506617A (OSRAM)
BR (1) BR112016006664A2 (OSRAM)
CA (1) CA2925218A1 (OSRAM)
IL (1) IL244730A0 (OSRAM)
IN (1) IN2013MU03015A (OSRAM)
WO (1) WO2015044960A2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626703A4 (en) * 2017-05-16 2020-12-16 Industry-Academic Cooperation Foundation, Yonsei University NEW COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THIS AS AN ACTIVE SUBSTANCE
CN113061118B (zh) * 2021-04-08 2022-05-27 株洲九派科技发展有限公司 一种吩嗪-查尔酮杂合化合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767919B2 (en) * 2002-12-17 2004-07-27 Walker Cancer Research Institute, Inc. High specificity anticancer agents
US6821983B2 (en) * 2003-04-04 2004-11-23 Academia Sinica 5-(9-acridinylamino)-toluidine compounds
WO2008135886A2 (en) * 2007-05-02 2008-11-13 University Of Pretoria Quinoline derivatives for use in the inhibition of the growth of tumour cells

Also Published As

Publication number Publication date
EP3049083A2 (en) 2016-08-03
IL244730A0 (en) 2016-04-21
EP3049083A4 (en) 2017-11-22
JP2017506617A (ja) 2017-03-09
CA2925218A1 (en) 2015-04-02
US20160214941A1 (en) 2016-07-28
IN2013MU03015A (OSRAM) 2015-07-17
WO2015044960A3 (en) 2017-01-19
WO2015044960A2 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
UA110338C2 (xx) Хімічні сполуки
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
AR124083A2 (es) Nuevo inhibidor de sglt1
IN2013DE02503A (OSRAM)
BR112016006664A2 (pt) compostos para a inibição do crescimento celular desregulado
DK201300179U1 (da) Kemisk forbindelse med nyttige egenskaber
EA201591449A1 (ru) Способы получения противораковых композиций
DOP2017000070A (es) Inhibidores cristalinos de bace
EA201690593A1 (ru) Новые соединения мочевины

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]